Incyte Jumps Into Genome Mapping; Investors Jump out
Executive Summary
Incyte Pharmaceuticals Inc. purchases Hexagen and creates a new business unit, Incyte Genetics, to be publicly traded as a tracking stock. Incyte Gentics' mission: to map the human genome within a year and generate SNP data for every human gene.